CN Patent

CN111094273B — 催产素受体抑制剂的晶型及其制备方法

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2022-04-12 · 4y expired

What this patent protects

提供催产素受体(OTR)抑制剂化合物5‑(3‑(3‑(6‑氟萘‑1‑基)氮杂环丁烷‑1‑基)5‑(甲氧基甲基)‑4H‑1,2,4‑三氮唑‑4‑基)‑2‑甲氧基吡啶的多晶型及其制备方法。相对于无定型而言，所述多晶型的OTR抑制剂具有更高的纯度，更优异的化学稳定性，对开发适合工业生产且生物活性良好的药物具有重要意义。

USPTO Abstract

提供催产素受体(OTR)抑制剂化合物5‑(3‑(3‑(6‑氟萘‑1‑基)氮杂环丁烷‑1‑基)5‑(甲氧基甲基)‑4H‑1,2,4‑三氮唑‑4‑基)‑2‑甲氧基吡啶的多晶型及其制备方法。相对于无定型而言，所述多晶型的OTR抑制剂具有更高的纯度，更优异的化学稳定性，对开发适合工业生产且生物活性良好的药物具有重要意义。

Drugs covered by this patent

Patent Metadata

Patent number
CN111094273B
Jurisdiction
CN
Classification
—
Expires
2022-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.